866-997-4948(US-Canada Toll Free)

Published on : Mar 03, 2017

ALBANY, NY, March 03, 2017: Although the death rates from non-Hodgkin lymphoma (NHL) have been on the decline since over a decade, the incidence and prevalence of this common cancer has been on a steady rise. The American Cancer Society, for instance, estimates that in 2017, an approximate 72,240 new cases of NHL will be diagnosed and around 20,140 people will succumb to this disease. This high prevalence is the primary factor driving the market for non-Hodgkin lymphoma. 

In a report recently added to ResearchMoz.us, the various types of NHL have been discussed and compared and the efforts by companies in the development of novel drugs have been evaluated. The report is titled “Non-Hodgkin Lymphoma - Heat Map and Analysis” and offers a clear and nuanced understanding of the market, the treatment options available, the studies conducted in the field, and the present late-stage pipeline. 

NHL, which is a group of blood cancers, can present itself in the form of various symptoms ranging from fever, weight loss, and tiredness to night sweats, bone pain, enlarged lymph nodes, and chest pain. The different treatment options of non-Hodgkin lymphoma include radiation, targeted therapy, surgery, chemotherapy, immunotherapy, and stem cell transplantation. The prominent therapeutic agents used to treat NHL include bortezomib, bleomycin, liposomal cytarabine, doxorubicin hydrochloride, methotrexate, cyclophosphamide, chlorambucil, and nelarabine. 

Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=970723

The market for non-Hodgkin lymphoma is driven by a number of factors. These include extensive research and development activities in the field, an increase in healthcare and medical expenditure, a focus on improving healthcare infrastructure in developing economies, and growing concern and awareness among the general population about this form of cancer. A number of clinical trials being undertaken to ascertain the efficacy of existing and pipeline drugs and therapeutics is also a key factor driving this market. on the contrary, the possible side effects of the various forms of treatment and high cost of research and development threaten to hamper the growth of this market. 

The report takes into account the overall landscape of the non-Hodgkin lymphoma market and charts its changing dynamics in the coming years. The potential of promising pipeline products and recently approved products has been discussed in depth, with the key focus points being efficacy and safety. The level of unmet needs around the world has also been identified and industry experts have offered inputs on how to optimize on these opportunities.

Geographically, North America and Europe have proven to be lucrative markets for non-Hodgkin lymphoma not only owing to the greater incidence of this cancer in the two regions but extensive research initiatives being undertaken here. In regions such as Asia Pacific, growing awareness about NHL is perhaps the most important factor boosting the market for the same. 

Some of the major participants in the global NHL market are Eli Lilly and Company, Amgen, Inc., F. Hoffmann LA Roche, Inc., AbbVie, Inc., Bayer AG, Pharmacyclics, Inc., Novartis International AG, and Nordic Nanovector A/S. 

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on sales@researchmoz.us